The Food and Drug Administration said it approved AstraZeneca’s (AZN) Koselugo for pediatric patients one year of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. The FDA previously approved Koselugo for pediatric patients two years of age and older with NF1 who have symptomatic, inoperable plexiform neurofibromas.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Trump signs memorandum mandating pharma ads give more info on risks
- AstraZeneca’s AZD2389 Phase I Study Completion: Key Insights for Investors
- AstraZeneca’s PROVIDENCE Study: Real-world Insights into Trastuzumab Deruxtecan for Metastatic Breast Cancer
- AstraZeneca’s Promising Phase II Study on AZD0901 for Advanced Solid Tumors
- AstraZeneca’s Latest Phase 4 Study: A Boost for HER2-Positive Breast Cancer Treatment?